USSTOCK.TODAY
Regular Market
Log in Sign up

Moderna Announces Real-World Study Results on mNEXSPIKE Vaccine Effectiveness in Older Adults

ACCESSWIRE +1 · ·by G4L

MRNA Moderna Inc
$248.69 -0.85%
View chart & analysis →
  1. 1Moderna, Inc. announced results from a large-scale real-world study involving 294,499 U.S. veterans.
  2. 2For the 2025-2026 respiratory virus season, mNEXSPIKE showed a 35.9% lower risk of COVID-19 requiring medical support compared to Comirnaty.
  3. 3For the 2025-2026 respiratory virus season, mNEXSPIKE showed a 47% lower risk of COVID-19-related hospitalization compared to Comirnaty.

So what's the key point?

Moderna confirmed the effectiveness of its new vaccine through a large study. The results show it is more effective by reducing the risk of hospitalization by 47% compared to the existing vaccine.

Source ACCESSWIRE +1 · View original ↗

Related 3-line summaries

BioNTech and Moderna Compete to Expand Beyond COVID-19 Vaccines into Cancer Treatment Market The Motley Fool +1 · 3d agoModerna achieves profitability with $1.4 billion in third-quarter revenue The Motley Fool · 4d agoModerna turns profitable in Q3 with $1.31 billion in revenue Investing.com · 4d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news